Black Diamond Therapeutics, Inc. (BDTX) is a Biotechnology company in the Healthcare sector, currently trading at $2.66. It has a SharesGrow Score of 81/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BDTX = $11.31 (+325.2% from the current price, the stock appears undervalued). Analyst consensus target is BDTX = $8 (+200.8% upside).
Valuation: BDTX trades at a trailing Price-to-Earnings (P/E) of 6.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Financials: revenue is $70M, +0%/yr average growth. Net income is $22M, growing at +50%/yr. Net profit margin is 32% (strong). Gross margin is 99.5% (+0 pp trend).
Balance sheet: total debt is $15M against $112M equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 8.42 (strong liquidity). Debt-to-assets is 10.5%. Total assets: $143M.
Analyst outlook: 9 / 10 analysts rate BDTX as buy (90%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 93/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income 100/100 (Pass).
